GeorgeBSelbyMD

Oncology • Oklahoma City, OK

Professor of Medicine, University Okla College of Medicine

Join to view full profile

Dr. Selby is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Selby's full profile

Already have an account?

Office
825 NE 10th St
Oupb 5200
Oklahoma City, OK 73104
Phone+1 405-271-8299

Education & Training

University of Oklahoma Health Sciences CenterFellowship, Hematology and Medical Oncology, 1983 - 1986
University of Oklahoma Health Sciences CenterResidency, Internal Medicine, 1980 - 1983
University of Oklahoma College of MedicineClass of 1980

Certifications & Licensure

OK State Medical License 1981 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Oklahoma Magazine Castle Connolly, 2008-2013
Top MD Consumers Checkbook

Clinical Trials

Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Start of enrollment: 2003 Dec 01
Completed
Phase 3
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) Start of enrollment: 2005 Sep 01
Completed
Phase 2
Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
Completed
Phase 3
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Start of enrollment: 2006 Nov 01
Completed
Phase 3
Adult Double Cord Blood Transplant Study Start of enrollment: 2007 Aug 01
Completed
Phase 2
Glucose Control In Hematopoetic Stem Cell Transplant Start of enrollment: 2007 Feb 01
Terminated
Not Applicable
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases Start of enrollment: 2005 Feb 01
Completed
Not Applicable
High Dose Chemo With Autologous BMT for Treatment of Metastatic Breast Cancer Start of enrollment: 1992 Jun 01
Completed
Not Applicable
Intensive Combo Chemo With Autologous BM Rescue for Metastatic Breast Cancer Start of enrollment: 1987 Oct 01
Completed
Phase 2
Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601) Start of enrollment: 2008 Aug 01
Completed
Phase 2
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) Start of enrollment: 2009 Apr 01
Completed
Phase 2
Stem Cell Related Donor Safety Study Start of enrollment: 2010 Jan 01
Completed
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901) Start of enrollment: 2011 Jun 01
Terminated
Phase 3
S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Aug 23
Active, not recruiting
Phase 3
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer Start of enrollment: 2012 Feb 01
Completed
Phase 2
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation Start of enrollment: 2012 Feb 01
Recruiting
Phase 2
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma Start of enrollment: 2013 Oct 01
Completed
Phase 2
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
Active, not recruiting
Phase 3
STRIDE Biorepository Start of enrollment: 2017 Mar 13
Recruiting
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

13 citations
Azacitidine Maintenance Therapy Post-Allogeneic Stem Cell Transplantation in Poor-Risk Acute Myeloid Leukemia.
Amany R Keruakous, Jennifer Holter-Chakrabarty, Sarah A Schmidt, Mohamad O Khawandanah, George Selby
Hematology/oncology and Stem Cell Therapy. 2023-01-12
2 citations
Incidence and risk factors for graft failure in the modern era of cord blood transplantation.
Jennifer Holter Chakrabarty, Joshua Glover, Sara Schmidt, Minh Phan, Michelle Bycko
Vox Sanguinis. 2022-12-01
32 citations
Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center.
Azra Borogovac, Amany Keruakous, Michelle Bycko, Jennifer Holter Chakrabarty, Sami Ibrahimi
Bone Marrow Transplantation. 2022-06-01

Journal Articles

Related Peripheral Blood Stem Cell Donors Experience More Severe Symptoms and Less Complete Recovery at 1-Year Compared to Unrelated Donors
Parameswaran N Hari, David A Jacobsohn, Joseph P McGuirk, Mary M Horowitz, Walter Longo, Thomas Spitzer, Daniel J Weisdorf, Shahram Mori, David C Delgado, Marcie L Ric..., Haematologica

Abstracts/Posters

Hypomethylating Agent Maintenance Therapy after Allogeneic Stem Cell Transplant Improves Transplant Outcome in High Risk Acute Myelogenous Leukemia
George Selby, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

Patient Following in Footsteps of Oklahoma Doctor Who Helped Save HimMarch 27th, 2021
New Technology Giving Hope to Oklahoma Cancer PatientsJune 12th, 2019
‘Major Breakthrough’: Oklahoma Doctors Unveil Revolutionary Cancer TreatmentJune 12th, 2019

Professional Memberships

American Society of Clinical Oncology - ASCO
Member